SCYX

$0.00

(

+0.00%

)
Quote details

stock

Scynexis Inc

NASDAQ | SCYX

0.99

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 18, 2025)

$41.51M

Market Cap

-

P/E Ratio

-0.4

EPS

$1.64

52 Week High

$0.66

52 Week Low

HEALTHCARE

Sector

SCYX Chart

Recent Chart
Price Action

SCYX Technicals

Tags:

SCYX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $3.7M
Total Revenue $3.7M
Cost Of Revenue $0
Costof Goods And Services Sold $0
Operating Income -$37M
Selling General And Administrative $14M
Research And Development $26M
Operating Expenses $41M
Investment Income Net -
Net Interest Income $1.7M
Interest Income $4.3M
Interest Expense $2.6M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.7M
Income Before Tax -$21M
Income Tax Expense $151K
Interest And Debt Expense -
Net Income From Continuing Operations -$21M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$19M
Net Income -$21M

Revenue & Profitability

Earnings Performance

SCYX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $91M
Total Current Assets $72M
Cash And Cash Equivalents At Carrying Value $16M
Cash And Short Term Investments $16M
Inventory -
Current Net Receivables $10M
Total Non Current Assets $18M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $16M
Short Term Investments $43M
Other Current Assets $2.6M
Other Non Current Assets -
Total Liabilities $36M
Total Current Liabilities $24M
Current Accounts Payable $4.6M
Deferred Revenue -
Current Debt -
Short Term Debt $15M
Total Non Current Liabilities $11M
Capital Lease Obligations $2.6M
Long Term Debt -
Current Long Term Debt $14M
Long Term Debt Noncurrent -
Short Long Term Debt Total $16M
Other Current Liabilities $3.4M
Other Non Current Liabilities -
Total Shareholder Equity $55M
Treasury Stock -
Retained Earnings -$377M
Common Stock $41K
Common Stock Shares Outstanding $49M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$24M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.7M
Capital Expenditures $0
Change In Receivables -
Change In Inventory $0
Profit Loss -
Cashflow From Investment $6.2M
Cashflow From Financing -$139K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$21M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $3.7M
Total Revenue $3.7M
Cost Of Revenue $0
Costof Goods And Services Sold $0
Operating Income -$37M
Selling General And Administrative $14M
Research And Development $26M
Operating Expenses $41M
Investment Income Net -
Net Interest Income $1.7M
Interest Income $4.3M
Interest Expense $2.6M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.7M
Income Before Tax -$21M
Income Tax Expense $151K
Interest And Debt Expense -
Net Income From Continuing Operations -$21M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$19M
Net Income -$21M

SCYX News

SCYX Profile

Scynexis Inc Profile

Sector: HEALTHCARE

Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC

Scynexis Inc. is a biotechnology firm headquartered in Jersey City, New Jersey, specializing in innovative therapies for the treatment of invasive fungal infections, with a particular focus on serious yeast infections. The company’s lead product candidate, BREXAFEMME®, is the first oral therapeutic specifically indicated for the treatment of vulvovaginal candidiasis, representing a significant advancement in antifungal therapy. With a robust pipeline and a commitment to addressing unmet medical needs in infectious diseases, Scynexis is well-positioned to enhance its market presence within the evolving landscape of antifungal treatments.

ATCH
+87.36%
$1.62
CGBS
-39.47%
$0.03
INTC
+25.22%
$31.18
BITF
+5.53%
$3.05
DVLT
+31.33%
$0.45
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
GRAB
-3.48%
$6.10
LYFT
+13.12%
$22.84
SOUN
+2.92%
$15.12
NEHC
-4.00%
$0.45
MARA
-1.08%
$17.34
RGTI
+9.94%
$21.99
TPIC
-45.91%
$0.12
F
+0.43%
$11.66
AXDX
-61.36%
$0.03
JOBY
-1.59%
$14.16
LYT
-16.77%
$0.09
LASE
+29.64%
$3.63
RR
+2.84%
$3.98
KDLY
-4.66%
$1.43
IONQ
+5.10%
$65.44
AVGO
-3.84%
$346.17
UBER
-4.98%
$92.95
AMZN
-1.03%
$231.62
MULN
-6.96%
$0.06
NVDA
+1.77%
$173.30
WULF
+3.74%
$11.35
VHAI
0.00%
$0.00
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
ADAP
+9.40%
$0.08
ETHD
-1.52%
$3.22
TLRY
-2.45%
$1.19
VALE
-0.27%
$10.88
SRM
+53.27%
$10.30
IREN
+3.97%
$37.90
SNAP
+5.61%
$8.43
CIFR
+7.55%
$12.38
RZLV
-3.26%
$7.11
CWD
+20.62%
$7.66
ETNB
+85.45%
$14.98
AMD
-3.21%
$154.04
PLUG
+0.03%
$2.00
BTE
-2.29%
$2.54
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
MRVL
+3.07%
$70.98
BABA
+2.44%
$166.17
WLGS
-5.57%
$0.04
RXRX
-2.68%
$4.71
BURU
-0.86%
$0.13
HBAN
+1.52%
$17.54
ORCL
-1.70%
$301.41
JBLU
0.00%
$5.07
ETWO
0.00%
$3.30
WMT
+0.82%
$104.27
HPE
+1.22%
$24.73
NBIS
+5.19%
$94.08
CRWV
+1.77%
$120.86
KDP
+1.11%
$27.26
AFMD
-34.94%
$0.18
YAAS
-4.19%
$0.06
PCG
+0.93%
$15.09
BMNR
+9.40%
$62.43
AMCR
-1.31%
$8.27
PBM
+32.79%
$4.94
NIO
-0.91%
$7.38
SLB
-1.27%
$34.79
BEEM
+15.01%
$2.91
BTBT
+2.36%
$3.03
SBET
+1.00%
$17.12
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
CSCO
+1.18%
$67.72
EQX
-1.51%
$10.40
SQFT
+46.29%
$8.88
KVUE
+1.15%
$18.34
PLTR
+4.30%
$175.57
ASTI
+15.38%
$2.25
AUR
-2.80%
$5.89
BIAF
-30.03%
$0.18
TSLA
+0.50%
$427.99
BCDA
-29.31%
$1.08
IAG
+0.18%
$11.03
BE
+8.70%
$79.67
ASST
-17.85%
$3.68
GIS
-0.76%
$49.18
QUBT
+5.47%
$18.67
IXHL
+3.78%
$0.54
SCHW
+1.16%
$92.09
NVNI
+29.17%
$1.04
AQB
+0.88%
$1.13
ZAPP
-46.30%
$0.15
UP
+6.31%
$2.19
QBTS
+0.02%
$22.54
XOM
+0.53%
$115.29
APVO
-6.00%
$1.41
USB
+2.52%
$49.61
RCAT
-10.20%
$10.11
ATCH
+87.36%
$1.62
CGBS
-39.47%
$0.03
INTC
+25.22%
$31.18
BITF
+5.53%
$3.05
DVLT
+31.33%
$0.45
NFE
+8.00%
$2.16
SPRC
+142.93%
$4.47
GRAB
-3.48%
$6.10
LYFT
+13.12%
$22.84
SOUN
+2.92%
$15.12
NEHC
-4.00%
$0.45
MARA
-1.08%
$17.34
RGTI
+9.94%
$21.99
TPIC
-45.91%
$0.12
F
+0.43%
$11.66
AXDX
-61.36%
$0.03
JOBY
-1.59%
$14.16
LYT
-16.77%
$0.09
LASE
+29.64%
$3.63
RR
+2.84%
$3.98
KDLY
-4.66%
$1.43
IONQ
+5.10%
$65.44
AVGO
-3.84%
$346.17
UBER
-4.98%
$92.95
AMZN
-1.03%
$231.62
MULN
-6.96%
$0.06
NVDA
+1.77%
$173.30
WULF
+3.74%
$11.35
VHAI
0.00%
$0.00
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
ADAP
+9.40%
$0.08
ETHD
-1.52%
$3.22
TLRY
-2.45%
$1.19
VALE
-0.27%
$10.88
SRM
+53.27%
$10.30
IREN
+3.97%
$37.90
SNAP
+5.61%
$8.43
CIFR
+7.55%
$12.38
RZLV
-3.26%
$7.11
CWD
+20.62%
$7.66
ETNB
+85.45%
$14.98
AMD
-3.21%
$154.04
PLUG
+0.03%
$2.00
BTE
-2.29%
$2.54
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
MRVL
+3.07%
$70.98
BABA
+2.44%
$166.17
WLGS
-5.57%
$0.04
RXRX
-2.68%
$4.71
BURU
-0.86%
$0.13
HBAN
+1.52%
$17.54
ORCL
-1.70%
$301.41
JBLU
0.00%
$5.07
ETWO
0.00%
$3.30
WMT
+0.82%
$104.27
HPE
+1.22%
$24.73
NBIS
+5.19%
$94.08
CRWV
+1.77%
$120.86
KDP
+1.11%
$27.26
AFMD
-34.94%
$0.18
YAAS
-4.19%
$0.06
PCG
+0.93%
$15.09
BMNR
+9.40%
$62.43
AMCR
-1.31%
$8.27
PBM
+32.79%
$4.94
NIO
-0.91%
$7.38
SLB
-1.27%
$34.79
BEEM
+15.01%
$2.91
BTBT
+2.36%
$3.03
SBET
+1.00%
$17.12
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
CSCO
+1.18%
$67.72
EQX
-1.51%
$10.40
SQFT
+46.29%
$8.88
KVUE
+1.15%
$18.34
PLTR
+4.30%
$175.57
ASTI
+15.38%
$2.25
AUR
-2.80%
$5.89
BIAF
-30.03%
$0.18
TSLA
+0.50%
$427.99
BCDA
-29.31%
$1.08
IAG
+0.18%
$11.03
BE
+8.70%
$79.67
ASST
-17.85%
$3.68
GIS
-0.76%
$49.18
QUBT
+5.47%
$18.67
IXHL
+3.78%
$0.54
SCHW
+1.16%
$92.09
NVNI
+29.17%
$1.04
AQB
+0.88%
$1.13
ZAPP
-46.30%
$0.15
UP
+6.31%
$2.19
QBTS
+0.02%
$22.54
XOM
+0.53%
$115.29
APVO
-6.00%
$1.41
USB
+2.52%
$49.61
RCAT
-10.20%
$10.11

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.